3653 results for «480»

Filter By

3653 results

Choosing the right tool to treat calcified bifurcation

19 May 2026 – From EuroPCR 2026

This session provides expert guidance on managing calcified bifurcation lesions. It highlights identification of high-risk scenarios, the role of coronary CT angiography and intravascular imaging in tool selection, and specialized techniques for treating calcified nodules in the left main coronary artery.

Choosing the right tool to treat calcified bifurcation

Outcomes in tricuspid valve intervention

19 May 2026 – From EuroPCR 2026

This session reviews contemporary clinical outcomes of tricuspid valve interventions. Topics include interim results from the Cardiovalve replacement system trial, the impact of atrial fibrillation on tricuspid TEER, residual regurgitation implications, afterload mismatch post-intervention, and long-term bioprosthetic valve durability.

Outcomes in tricuspid valve intervention

Addressing complications in calcified lesions

19 May 2026 – From EuroPCR 2026

This session delves into the complexities and management strategies for complications arising in calcified coronary lesions. Topics include advanced techniques such as puncturing the seal, handling lethal complications on calcified vessels, managing rare rotational atherectomy wire fractures, addressing massive stent deformation due to jailed rotawires, innovative...

Addressing complications in calcified lesions

Repair or replace the tricuspid valve: how to decide?

19 May 2026 – From EuroPCR 2026

This session focuses on decision-making in tricuspid valve interventions, balancing the choice between repair and replacement. It covers clinical and anatomical criteria guiding treatment selection, pacing lead management from an electrophysiological and surgical perspective, and the application of multimodality imaging—including TTE, TOE, and CT—to inform real-world...

Repair or replace the tricuspid valve: how to decide?

Interventional therapy for hypertension

19 May 2026 – From EuroPCR 2026

This session addresses interventional therapies for hypertension, emphasizing patient selection for renal denervation and integration of this technique within comprehensive hypertension management. It also reviews available renal denervation technologies, optimal procedural approaches, and considerations for interventional treatment of renal artery stenosis.

Interventional therapy for hypertension

RESIL-Card in action: early European experience and lessons from the first users

19 May 2026 – From EuroPCR 2026

This session presents the early European experience with the RESIL-Card tool, designed to optimize interventional cardiology care pathways during crises. It includes practical insights from early adopters, updates on dissemination efforts across Europe, strategies for engaging patients and organizations, and discussions on national and EU political...

CathWorks FFRangio: from clinical data to advanced patient care

21 May 2026 – From EuroPCR 2026

Explore the clinical value of the CathWorks FFRangio system through the lens of the ALL-RISE randomised controlled trial and its implications for daily practice. By reviewing the trial’s primary and secondary endpoints, examine how FFRangio may influence diagnostic assessment, treatment planning, and clinical decision-making in patients...

CathWorks FFRangio: from clinical data to advanced patient care

Renal denervation in China: momentum, insights, and evolution

21 May 2026 – From EuroPCR 2026

This EuroPCR 2026 session highlights the rapidly evolving clinical experience of renal denervation (RDN) in China following regulatory approval, with a focus on real-world practice and programme development.

It reviews how structured, patient-centred hypertension pathways are being integrated with RDN, alongside practical strategies for managing complex renal...

Renal denervation in China: momentum, insights, and evolution

Expanding the horizon - Trials addressing unchartered territories in coronary and structural heart

20 May 2026 – From EuroPCR 2026

New clinical evidence is pushing coronary and structural heart therapy into areas that were previously uncertain or inconsistently defined, with multiple landmark trials now shaping future practice.

Among the studies discussed in this EuroPCR 2026 session, are SORT OUT XII, START YOUNG, BISCUSPID, LANDMARK 2 and RESTORE...

Expanding the horizon - Trials addressing unchartered territories in coronary and structural heart

The metal-free strategy: shaping the new era of hybrid vessel restoration with DCB and BRS

19 May 2026 – From EuroPCR 2026

This EuroPCR 2026 session explores the emerging metal-free strategy in coronary intervention, combining drug-coated balloons (DCB) and bioresorbable scaffolds (BRS) to support a “leave-nothing-behind” approach to vessel restoration.

It focuses on lesion preparation, scaffold sizing and deployment, and the integration of hybrid therapies to optimise procedural outcomes....

The metal-free strategy: shaping the new era of hybrid vessel restoration with DCB and BRS

All you need to know about interventional therapies for pulmonary embolism

20 May 2026 – From EuroPCR 2026

Focused on interventional therapies for pulmonary embolism, this session guides on establishing and sustaining Pulmonary Embolism Response Teams (PERT), refining patient selection for intervention, choosing appropriate technologies, and identifying intraprocedural markers indicating successful treatment outcomes.

All you need to know about interventional therapies for pulmonary embolism

TAVI procedural complications - Part 5: vascular complications, coronary issues and more

20 May 2026 – From EuroPCR 2026

This session addresses procedural complications during TAVI, focusing on vascular complications, coronary issues, and rare device-related events. It includes case analyses of aortic dissection, valve infolding, stent dislodgement, and management strategies for complex anatomical challenges.

TAVI procedural complications - Part 5: vascular complications, coronary issues and more

Antithrombotic therapy after TAVI: optimal agents, regimens, and patient selection

20 May 2026 – From EuroPCR 2026

This session critically evaluates antithrombotic therapy following TAVI, addressing optimal agents and regimens tailored to patients with and without atrial fibrillation. It also reviews clinical presentations and management of valve thrombosis post-TAVI, using guideline-based approaches and real-world cases to individualize patient care.

Antithrombotic therapy after TAVI: optimal agents, regimens, and patient selection

Tackling calcified lesions with IVUS guidance and optimisation

20 May 2026 – From EuroPCR 2026

This session delves into the critical role of Intravascular Ultrasound (IVUS) in characterizing and managing calcified coronary lesions. Attendees can explore an imaging-guided approach to calcium treatment, including case presentations that demonstrate stent selection and procedural optimization. Emphasis is placed on applying imaging-based optimization metrics to...

Tackling calcified lesions with IVUS guidance and optimisation

Unusual complexities, uncommon complications and innovative solutions

20 May 2026 – From EuroPCR 2026

This session showcases innovative solutions to unusual complexities and rare complications in interventional cardiology. Through detailed case presentations, it examines ambiguous CTO management, giant coronary aneurysm complications post-PCI, and unforeseen issues arising from coronary atherectomy for calcified nodules.

Unusual complexities, uncommon complications and innovative solutions

When to best combine guided-directed medical therapy and devices at discharge of acute heart failure

20 May 2026 – From EuroPCR 2026

This session addresses the challenges and strategies in optimizing guided-directed medical therapy for acute heart failure patients, especially those intolerant to up-titration. It also covers the assessment and timing for cardiac resynchronisation therapy (CRT), highlighting the benefits of combining medical therapy and device implantation to improve...

When to best combine guided-directed medical therapy and devices at discharge of acute heart failure

Registries and trials in mitral TEER

20 May 2026 – From EuroPCR 2026

This comprehensive session reviews registries and clinical trials in mitral transcatheter edge-to-edge repair (TEER). It includes discussions on novel TEER systems, international consensus on PASCAL implants, anatomical predictors of procedural success, and long-term outcomes including ventricular and atrial remodeling after intervention, as well as emerging therapies...

Other valvular and structural interventions

20 May 2026 – From EuroPCR 2026

Covering a spectrum of valvular and structural heart interventions, this session discusses systemic aortic valve TEER in complex congenital cases, compares TAVI and surgical AVR outcomes via meta-analysis, highlights radiation protection advances in complex endovascular repair, and presents combined mitral and tricuspid TEER techniques, novel ultrasound...

Other valvular and structural interventions

Monotherapy vs. DAPT: striking the balance between ischemia and bleeding

20 May 2026 – From EuroPCR 2026

This session examines the balance between ischemic and bleeding risks by comparing monotherapy regimens and dual antiplatelet therapy (DAPT) following PCI. Key topics include clopidogrel versus aspirin monotherapy, aspirin discontinuation timing after ACS, and the impact of P2Y12 adherence on clinical outcomes in high-risk and oral...

Dangers of dissection: the role of ICI

20 May 2026 – From EuroPCR 2026

This session explores the critical role of intracoronary imaging (ICI) in diagnosing and managing coronary artery dissections. Cases include fenestration techniques, stent migration challenges, polytrauma patient management, route selection dilemmas, and intricate procedural navigation to achieve successful outcomes.

Dangers of dissection: the role of ICI
Didn’t find what you were looking for?